Get started
Author

Sergio Fonseca

Observed names: Fonseca, Sergio, Fonseca, Sérgio Luís Martins, Sergio A. Fonseca
Observed institution: Johnson & Johnson (United States)
ORCID: 0009-0008-3687-5964
Observed ORCID: 0009-0008-3687-5964
OpenAlex ID: A5000407449
Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes
2025 · Ulhas Nadgir, Saberi Rana Ali, et al. · Annals of Internal Medicine · 6
Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching
2026 · Zhong Yuan, Carolyn H. Jeffcoat, et al. · PLoS ONE · 2
PDF
Golimumab for the Treatment of Axial Spondyloarthritis: Integrating Clinical Outcomes with Real-World Patient Benefits
2026 · Atul Deodhar, Tae-Jong Kim, et al. · Advances in Therapy
PDF
Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies
2026 · Uta Kiltz, Yi-Ming Chen, et al. · Rheumatology and Therapy
PDF
A study on the utilization of canagliflozin in type 1 diabetes mellitus using real‐world data from four European countries
2025 · Erica A. Voss, Zhong Yuan, et al. · Diabetes Obesity and Metabolism
Relationship between canagliflozin use and sarcopenia: Real-world data from the United States
2025 · Zhong Yuan, Jill Hardin, et al. · Diabetes Epidemiology and Management
Fatores associados à mortalidade e funcionalidade pós hemorragia intracerebral espontânea
2019 · Fonseca, Sérgio Luís Martins · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
PDF
Works count: 8
Citation count: 8
H-index: 2
I10-index:
Year
Topic
Type